TY - JOUR
T1 - Localised and unresectable neuroblastoma in infants
T2 - Excellent outcome with primary chemotherapy
AU - David, Kerstin
AU - Heiligtag, Sven
AU - Ollert, Markus W.
AU - Teppke, Manfred
AU - Vogel, Carl Wilhelm
AU - Bredehorst, Reinhard
PY - 2001
Y1 - 2001
N2 - Procedure. Infants with neuroblastoma·(NB) were assessed according to INSS recommendations, including MIBG scan and extensive bone marrow staging to eliminate metastatic spread. Patients with unresectable tumour received chemotherapy, including two courses of carboplatin-etoposide (CE) and two of vincristinecyclophosphamide-doxorubicin (CAdO). Postoperative treatment was to be given only in infants with MYCN amplification. Between 1990 and 1994, 52 consecutive children were registered. Results. Among the 44 patients who received CE as a first course, the response rate was 66% and the primary could be removed in all children but one, who was in remission. The toxicity was mainly haematological and was always manageable. The 5 year overall survival (OS) and event-free survival (EFS) were 94 and 90 ± 8%, respectively, with a median follow-up of 48 months. The outcome of infants with no MYCN amplification was excellent; OS and EFS were, respectively, 97 and 94%. Conclusions. Chemotherapy allows surgical excision and excellent outcome in infants with localised and unresectable NB. Less intensive Chemotherapy should be investigated in such patients.
AB - Procedure. Infants with neuroblastoma·(NB) were assessed according to INSS recommendations, including MIBG scan and extensive bone marrow staging to eliminate metastatic spread. Patients with unresectable tumour received chemotherapy, including two courses of carboplatin-etoposide (CE) and two of vincristinecyclophosphamide-doxorubicin (CAdO). Postoperative treatment was to be given only in infants with MYCN amplification. Between 1990 and 1994, 52 consecutive children were registered. Results. Among the 44 patients who received CE as a first course, the response rate was 66% and the primary could be removed in all children but one, who was in remission. The toxicity was mainly haematological and was always manageable. The 5 year overall survival (OS) and event-free survival (EFS) were 94 and 90 ± 8%, respectively, with a median follow-up of 48 months. The outcome of infants with no MYCN amplification was excellent; OS and EFS were, respectively, 97 and 94%. Conclusions. Chemotherapy allows surgical excision and excellent outcome in infants with localised and unresectable NB. Less intensive Chemotherapy should be investigated in such patients.
UR - http://www.scopus.com/inward/record.url?scp=0035161768&partnerID=8YFLogxK
U2 - 10.1002/1096-911X(20010101)36:1<247::AID-MPO1061>3.0.CO;2-Z
DO - 10.1002/1096-911X(20010101)36:1<247::AID-MPO1061>3.0.CO;2-Z
M3 - Article
C2 - 11464897
AN - SCOPUS:0035161768
SN - 0098-1532
VL - 36
SP - 247
EP - 250
JO - Medical and Pediatric Oncology
JF - Medical and Pediatric Oncology
IS - 1
ER -